Pharming Group (PHAR) Competitors $10.96 -0.15 (-1.35%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.99 +0.03 (+0.26%) As of 08/1/2025 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAR vs. OGN, NAMS, RXRX, GMTX, RARE, MIRM, CPRX, AMRX, IBRX, and BHCShould you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Organon & Co. (OGN), NewAmsterdam Pharma (NAMS), Recursion Pharmaceuticals (RXRX), Gemini Therapeutics (GMTX), Ultragenyx Pharmaceutical (RARE), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Amneal Pharmaceuticals (AMRX), ImmunityBio (IBRX), and Bausch Health Cos (BHC). These companies are all part of the "pharmaceutical products" industry. Pharming Group vs. Its Competitors Organon & Co. NewAmsterdam Pharma Recursion Pharmaceuticals Gemini Therapeutics Ultragenyx Pharmaceutical Mirum Pharmaceuticals Catalyst Pharmaceuticals Amneal Pharmaceuticals ImmunityBio Bausch Health Cos Pharming Group (NASDAQ:PHAR) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability. Is PHAR or OGN more profitable? Organon & Co. has a net margin of 11.92% compared to Pharming Group's net margin of -2.19%. Organon & Co.'s return on equity of 227.43% beat Pharming Group's return on equity.Company Net Margins Return on Equity Return on Assets Pharming Group-2.19% -3.38% -1.82% Organon & Co. 11.92%227.43%7.34% Do analysts rate PHAR or OGN? Pharming Group currently has a consensus target price of $30.00, suggesting a potential upside of 173.72%. Organon & Co. has a consensus target price of $18.00, suggesting a potential upside of 84.43%. Given Pharming Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe Pharming Group is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Organon & Co. 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 Do institutionals and insiders believe in PHAR or OGN? 0.0% of Pharming Group shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 2.0% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, PHAR or OGN? Organon & Co. has higher revenue and earnings than Pharming Group. Pharming Group is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharming Group$297.20M2.53-$11.84M-$0.13-84.31Organon & Co.$6.40B0.40$864M$2.883.39 Does the media prefer PHAR or OGN? In the previous week, Pharming Group had 5 more articles in the media than Organon & Co.. MarketBeat recorded 9 mentions for Pharming Group and 4 mentions for Organon & Co.. Pharming Group's average media sentiment score of 1.08 beat Organon & Co.'s score of 1.04 indicating that Pharming Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, PHAR or OGN? Pharming Group has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. SummaryOrganon & Co. beats Pharming Group on 10 of the 17 factors compared between the two stocks. Get Pharming Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAR vs. The Competition Export to ExcelMetricPharming GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$761.20M$3.00B$5.48B$9.52BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-84.3117.6228.6723.80Price / Sales2.53178.97373.5466.64Price / Cash149.8841.9535.4557.96Price / Book3.378.508.275.55Net Income-$11.84M-$55.06M$3.24B$259.03M7 Day Performance6.82%-3.98%-3.69%-4.59%1 Month Performance2.91%9.59%4.33%4.46%1 Year Performance51.17%6.72%25.95%18.03% Pharming Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHARPharming Group3.0169 of 5 stars$10.96-1.4%$30.00+173.7%+43.1%$761.20M$297.20M-84.31280News CoveragePositive NewsEarnings ReportGap DownHigh Trading VolumeOGNOrganon & Co.4.8856 of 5 stars$9.96-2.4%$18.00+80.7%-54.9%$2.65B$6.40B3.464,000Positive NewsUpcoming EarningsNAMSNewAmsterdam Pharma3.2139 of 5 stars$23.42-0.8%$41.30+76.3%+23.4%$2.65B$45.56M-12.464Positive NewsUpcoming EarningsRXRXRecursion Pharmaceuticals1.5175 of 5 stars$6.31-2.8%$7.00+10.9%-22.6%$2.64B$58.84M-3.56400Upcoming EarningsGap DownGMTXGemini TherapeuticsN/A$60.61+0.0%N/A+38.5%$2.63BN/A-60.6130RAREUltragenyx Pharmaceutical4.4732 of 5 stars$27.61+1.0%$82.57+199.1%-35.6%$2.58B$560.23M-4.701,294Analyst RevisionMIRMMirum Pharmaceuticals3.7376 of 5 stars$51.49-0.7%$65.50+27.2%+29.6%$2.57B$336.89M-31.98140News CoveragePositive NewsUpcoming EarningsCPRXCatalyst Pharmaceuticals4.8982 of 5 stars$20.80-0.8%$32.83+57.9%+24.7%$2.56B$491.73M13.2580Positive NewsUpcoming EarningsAMRXAmneal Pharmaceuticals3.5296 of 5 stars$8.17+1.4%$11.60+42.0%+9.1%$2.53B$2.79B-204.208,100Positive NewsIBRXImmunityBio2.2348 of 5 stars$2.65-7.3%$12.25+362.3%-50.5%$2.52B$14.74M-4.57590News CoverageGap DownBHCBausch Health Cos4.6465 of 5 stars$6.88+1.6%$7.38+7.2%-6.4%$2.51B$9.63B-62.5520,700News CoverageEarnings ReportAnalyst Upgrade Related Companies and Tools Related Companies OGN Competitors NAMS Competitors RXRX Competitors GMTX Competitors RARE Competitors MIRM Competitors CPRX Competitors AMRX Competitors IBRX Competitors BHC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group N.V. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHAR Stock Alerts